Atrys Health, S.A. (BME:ATRY) signed an agreement to acquire Simm Molecular from Isabel Roca and Joan Castell for €5.8 million on December 16, 2021. €5.2 million paid on the date of signing the operation and €0.6 million of contingent payment payable in the next 3 years from the date of signing the operation. Atrys will finance the acquisition with its own resources and does not entail the issuance of new Atrys shares. Isabel Roca and Joan Castell with their current team, will lead the area of Nuclear Medicine of the Atrys Group in Spain. The acquisition is expected to take place in January 2022. Guerrero de Castro Law Firm acted as legal advisor to Simm Molecular. RAUL LOPEZ MORO of BDO Auditores, S.L.P. acted as due diligence provider to Atrys Health, S.A. BDO Financial Advisory acted as financial advisor to Atrys Health.

Atrys Health, S.A. (BME:ATRY) completed the acquisition of Simm Molecular from Isabel Roca and Joan Castell on January 4, 2022.